EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ABACHAI phase 2 clinical trial: Safety and efficacy of subcutaneous abatacept in patients with CTLA-4 insufficiency or LRBA deficiency

Máté Krausz, Georgios Sogkas, Annette Uhlmann, Gabriele Ihorst, Sigune Goldacker, Torsten Witte, Manuel Feißt, Laia Alsina, Ingunn Dybedal, Mike Recher, Klaus Warnatz, Bodo Grimbacher

Journal of Allergy and Clinical Immunology · 2026-09

DOI: 10.1016/j.jaci.2026.09.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-09. Verfasst von Máté Krausz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-Un…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Wilhelm Sander-Stiftung, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Heterozygous germline mutations in CTLA4 (CTLA-4 insufficiency) and biallelic mutations in LRBA (lipopolysaccharide-responsive beige-like anchor protein [LRBA] deficiency) cause immune dysregulation with autoimmunity, lymphoproliferation, and immunodeficiency. For treatment, abatacept has been used successfully and is increasingly being used off-label; however, prospective clinical trial data are missing. OBJECTIVE: We evaluated the safety and efficacy of abatacept in patients with CTLA-4 insufficiency or LRBA deficiency. METHODS: ABACHAI was a prospective, open-label, single-arm phase 2a trial. Adult patients with genetically confirmed CTLA-4 insufficiency or LRBA deficiency and at least one clinically significant organ manifestation received 125 mg abatacept subcutaneously once a week for 12 months. The primary end point was safety, defined as the number of episodes of failed infection control. Secondary end points included additional safety parameters, efficacy outcomes, and patient-reported quality of life. RESULTS: Twenty patients were enrolled (18 with CTLA-4 insufficiency and 2 with LRBA deficiency). Three patients had 5 severe infections during treatment (incidence rate, 0.27 per patient-year), comparable to the year before enrollment. No Epstein-Barr virus or cytomegalovirus reactivations occurred. Abatacept reduced lymphoproliferation and immune activation and improved patient-reported quality of life and gastrointestinal symptom quality. Cytopenias and renal involvement were not sufficiently controlled. Four patients (20%) discontinued therapy, 3 because of unrelated serious adverse events and 1 because of noncompliance. CONCLUSION: ABACHAI was the first prospective interventional trial examining abatacept treatment in CTLA-4 insufficiency and LRBA deficiency. Abatacept demonstrated a favorable safety profile and organ-specific efficacy, with strongest responses in lymphoproliferation and immune activation. Patients with refractory cytopenias or progressive organ involvement may require additional or alternative therapeutic strategies.

Schlagwörter

Stichwörter der Autor:innen

CTLA-4 insufficiencyLRBA deficiencyabataceptautoimmunityclinical trialcommon variable immunodeficiencyimmunodeficiencylymphoproliferation

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany; Institute for Immunodeficienc…
  • Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Institute for Immunodeficiency, CCI, Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany; Clinical Trials Unit, University of Freiburg, Medical Center, Faculty of Medicine, Albe…
  • Clinical Trials Unit, University of Freiburg, Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
  • Department of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
  • Institute of Medical Biometry, Heidelberg University Hospital, Heidelberg, Germany.

Förderung

  • Bristol Myers Squibb
  • Wilhelm Sander-Stiftung
  • Deutsche Forschungsgemeinschaft
  • Bundesministerium fur Bildung und Forschung Dienststelle Bonn
  • Horizon Europe

Zitieren

APA

Krausz, M., Sogkas, G., Uhlmann, A., Ihorst, G., Goldacker, S., Witte, T., Feißt, M., Alsina, L., Dybedal, I., Recher, M., Warnatz, K., & Grimbacher, B. (2026). ABACHAI phase 2 clinical trial: Safety and efficacy of subcutaneous abatacept in patients with CTLA-4 insufficiency or LRBA deficiency. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2026.09.007

Vancouver

Krausz M, Sogkas G, Uhlmann A, Ihorst G, Goldacker S, Witte T, et al. ABACHAI phase 2 clinical trial: Safety and efficacy of subcutaneous abatacept in patients with CTLA-4 insufficiency or LRBA deficiency. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.09.007

BibTeX
@article{Krausz2026,
  author = {Krausz, Máté and Sogkas, Georgios and Uhlmann, Annette and Ihorst, Gabriele and Goldacker, Sigune and Witte, Torsten and Feißt, Manuel and Alsina, Laia and Dybedal, Ingunn and Recher, Mike and Warnatz, Klaus and Grimbacher, Bodo},
  title = {ABACHAI phase 2 clinical trial: Safety and efficacy of subcutaneous abatacept in patients with CTLA-4 insufficiency or LRBA deficiency},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  doi = {10.1016/j.jaci.2026.09.007}
}
Kostenlos starten →